287 related articles for article (PubMed ID: 31791666)
1. Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease.
Liang X; Wang P; Chen B; Ge Y; Gong AY; Flickinger B; Malhotra DK; Wang LJ; Dworkin LD; Liu Z; Gong R
Kidney Int; 2020 Jan; 97(1):175-192. PubMed ID: 31791666
[TBL] [Abstract][Full Text] [Related]
2. The redox-sensitive GSK3β is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease.
Chen M; Fang Y; Ge Y; Qiu S; Dworkin L; Gong R
Redox Biol; 2024 Jun; 72():103127. PubMed ID: 38527400
[TBL] [Abstract][Full Text] [Related]
3. GSK-3β inhibitor attenuates urinary albumin excretion in type 2 diabetic db/db mice, and delays epithelial-to-mesenchymal transition in mouse kidneys and podocytes.
Wan J; Li P; Liu DW; Chen Y; Mo HZ; Liu BG; Chen WJ; Lu XQ; Guo J; Zhang Q; Qiao YJ; Liu ZS; Wan GR
Mol Med Rep; 2016 Aug; 14(2):1771-84. PubMed ID: 27357417
[TBL] [Abstract][Full Text] [Related]
4. Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus.
Satirapoj B; Tassanasorn S; Charoenpitakchai M; Supasyndh O
PLoS One; 2015; 10(4):e0124055. PubMed ID: 25884625
[TBL] [Abstract][Full Text] [Related]
5. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
Li HY; Oh YS; Choi JW; Jung JY; Jun HS
Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy.
Yamaguchi Y; Iwano M; Suzuki D; Nakatani K; Kimura K; Harada K; Kubo A; Akai Y; Toyoda M; Kanauchi M; Neilson EG; Saito Y
Am J Kidney Dis; 2009 Oct; 54(4):653-64. PubMed ID: 19615802
[TBL] [Abstract][Full Text] [Related]
7. GSK3β-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition.
Lu M; Wang P; Qiao Y; Jiang C; Ge Y; Flickinger B; Malhotra DK; Dworkin LD; Liu Z; Gong R
Redox Biol; 2019 Sep; 26():101275. PubMed ID: 31349118
[TBL] [Abstract][Full Text] [Related]
8. The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults.
Fang Y; Chen B; Gong AY; Malhotra DK; Gupta R; Dworkin LD; Gong R
Kidney Int; 2021 Nov; 100(5):1037-1053. PubMed ID: 34246657
[TBL] [Abstract][Full Text] [Related]
9. Urinary DcR2 is a novel biomarker for tubulointerstitial injury in patients with diabetic nephropathy.
Chen J; Zhang WW; Chen KH; Lin LR; Dai HZ; Li KL; Zhang JG; Zheng LQ; Fu BQ; He YN
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F273-F281. PubMed ID: 28356293
[TBL] [Abstract][Full Text] [Related]
10. Intrarenal and Urinary Glycogen Synthase Kinase-3 Beta Levels in Diabetic and Nondiabetic Chronic Kidney Disease.
Zeng L; Ng JK; Fung WW; Chan GC; Chow KM; Szeto CC
Kidney Blood Press Res; 2023; 48(1):241-248. PubMed ID: 36940673
[TBL] [Abstract][Full Text] [Related]
11. Permissive effect of GSK3β on profibrogenic plasticity of renal tubular cells in progressive chronic kidney disease.
Chen B; Wang P; Liang X; Jiang C; Ge Y; Dworkin LD; Gong R
Cell Death Dis; 2021 Apr; 12(5):432. PubMed ID: 33931588
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase‑3β is required for epithelial‑mesenchymal transition and barrier dysfunction in mouse podocytes under high glucose conditions.
Guo J; Yang L; Qiao Y; Liu Z
Mol Med Rep; 2016 Nov; 14(5):4091-4098. PubMed ID: 27748847
[TBL] [Abstract][Full Text] [Related]
13. RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease.
Guo J; Lei M; Cheng F; Liu Y; Zhou M; Zheng W; Zhou Y; Gong R; Liu Z
Cell Death Dis; 2020 Jun; 11(6):413. PubMed ID: 32487989
[TBL] [Abstract][Full Text] [Related]
14. Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury.
Mariappan MM; Prasad S; D'Silva K; Cedillo E; Sataranatarajan K; Barnes JL; Choudhury GG; Kasinath BS
J Biol Chem; 2014 Dec; 289(51):35363-75. PubMed ID: 25339176
[TBL] [Abstract][Full Text] [Related]
15. FABP1 and FABP2 as markers of diabetic nephropathy.
Tsai IT; Wu CC; Hung WC; Lee TL; Hsuan CF; Wei CT; Lu YC; Yu TH; Chung FM; Lee YJ; Wang CP
Int J Med Sci; 2020; 17(15):2338-2345. PubMed ID: 32922199
[No Abstract] [Full Text] [Related]
16. HGF protected against diabetic nephropathy via autophagy-lysosome pathway in podocyte by modulating PI3K/Akt-GSK3β-TFEB axis.
Hou B; Li Y; Li X; Zhang C; Zhao Z; Chen Q; Zhang N; Li H
Cell Signal; 2020 Nov; 75():109744. PubMed ID: 32827692
[TBL] [Abstract][Full Text] [Related]
17. Reduced LRP6 expression and increase in the interaction of GSK3β with p53 contribute to podocyte apoptosis in diabetes mellitus and are prevented by green tea.
Peixoto EB; Papadimitriou A; Teixeira DA; Montemurro C; Duarte DA; Silva KC; Joazeiro PP; Lopes de Faria JM; Lopes de Faria JB
J Nutr Biochem; 2015 Apr; 26(4):416-30. PubMed ID: 25655048
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis.
Mohamed R; Jayakumar C; Chen F; Fulton D; Stepp D; Gansevoort RT; Ramesh G
J Am Soc Nephrol; 2016 Mar; 27(3):745-65. PubMed ID: 26334030
[TBL] [Abstract][Full Text] [Related]
19. Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy: A prospective cohort study.
Satirapoj B; Pooluea P; Nata N; Supasyndh O
J Diabetes Complications; 2019 Sep; 33(9):675-681. PubMed ID: 31227289
[TBL] [Abstract][Full Text] [Related]
20. Pathological significance of urinary complement activation in diabetic nephropathy: A full view from the development of the disease.
Zheng JM; Jiang ZH; Chen DJ; Wang SS; Zhao WJ; Li LJ
J Diabetes Investig; 2019 May; 10(3):738-744. PubMed ID: 30239170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
